½ÃÀ庸°í¼­
»óǰÄÚµå
1562199

ºÏ¹ÌÀÇ ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - À¯Çü, Á¦Ç°, ±â¼ú, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº°

North America Rapid Test Kit Market Forecast to 2030 - Regional Analysis - by Type, Product, Technology, Application, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 157 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀº 2022³â 68¾ï 6,940¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2030³â¿¡´Â 104¾ï 6,282¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö 5.4%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

À¯Àüº´ ¹× °¨¿°¼º ÁúȯÀÇ À¯ÇàÀ¸·Î ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå Ȱ¼ºÈ­

MJH Life Sciences(¹Ì±¹)ÀÇ 2022³â º¸°í¼­¿¡ µû¸£¸é, Àü ¼¼°èÀûÀ¸·Î ¸Å³â 30¸¸ ¸íÀÇ ½Å»ý¾Æ°¡ °â»óÀûÇ÷±¸ÁõÀ¸·Î ž´Â °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, CDC¿¡ µû¸£¸é ¾ÆÇÁ¸®Ä«°è ¹Ì±¹ÀÎ 500¸í Áß 1¸íÀÌ °â»óÀûÇ÷±¸ÁõÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)°¡ ¹ßÇ¥ÇÑ Ãֽм¼°è ¸»¶ó¸®¾Æ º¸°í¼­(WMR) 2022¿¡ µû¸£¸é, 2021³â Àü ¼¼°è¿¡¼­ »õ·Î º¸°íµÈ ¸»¶ó¸®¾Æ ȯÀÚ´Â ¾à 2¾ï 4,700¸¸ ¸í, 2020³â¿¡´Â 2¾ï 4,500¸¸ ¸íÀ¸·Î Áý°èµÆ½À´Ï´Ù. ÀÚ·á¿¡ µû¸£¸é 2021³â ¸»¶ó¸®¾Æ·Î ÀÎÇÑ »ç¸ÁÀÚ ¼ö´Â 619,000¸íÀ̾ú½À´Ï´Ù.

Sickle SCANÀº °â»ó ÀûÇ÷±¸ ºóÇ÷À» ³ôÀº ¹Î°¨µµ¿Í ƯÀ̵µ·Î ½Äº°ÇÏ´Â ½Å¼Ó °Ë»çÀÔ´Ï´Ù. ½Å¼Ó Áø´Ü °Ë»ç(RDT)´Â Àΰ£ Ç÷¾×¿¡¼­ ¸»¶ó¸®¾Æ ¿øÃæÀÇ Á¸À縦 °¨ÁöÇÏ¿© ¸»¶ó¸®¾Æ¸¦ Áø´ÜÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¾çÁúÀÇ Çö¹Ì°æ °Ë»ç ¼­ºñ½º¿¡ ´ëÇÑ Á¢±ÙÀÌ Á¦ÇÑÀûÀÎ °æ¿ì ¹æ»ç¼± Áø´Ü ±â¼úÀº ÀÓ»ó Áø´Ü ¹× Çö¹Ì°æ Áø´ÜÀÇ ´ë¾ÈÀ¸·Î »ç¿ëµÇ¸ç, COVID-19ÀÇ ´ëÀ¯ÇàÀº ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. °ÅÀÇ ¸ðµç Áø´Ü °Ë»ç¿¡¼­ ½Ç½Ã°£ PCRÀº SARS-CoV-2 °¨¿° Áõ»óÀ» º¸ÀÌ´Â »ç¶÷µéÀ» °Ë»çÇÏ´Â µ¥ »ç¿ëµÇ¾ú½À´Ï´Ù. ½Å¼Ó °Ë»ç ŰƮ´Â °ÅÀÇ ¸ðµç °÷¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖÀ¸¸ç °­·ÂÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ëºÎºÐÀÇ ºÐÀÚ»ý¹°ÇÐ ¿¬±¸¼Ò¿¡¼­ À¯ÀüÀÚÇü ºÐ¼®, Ŭ·Î´×, ´ÜÀÏ¿°±âº¯ÀÌ ºÐ¼®À» À§ÇØ Æ¯Á¤ DNA ½ºÆ®·¹Ä¡ÀÇ ÁõÆøÀ» ¼ö¹ÝÇÏ´Â ½Å¼Ó °Ë»ç ±â¼úÀ» »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌó·³ À¯Àü Áúȯ ¹× °¨¿°¼º ÁúȯÀÇ ¹ßº´·ü Áõ°¡´Â ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå °³¿ä

¿¬±¸ ¹× Ä¡·á¿¡¼­ CRISPR, PCR µî À¯ÀüÀÚ ÇÕ¼º ¹× ÆíÁý µµ±¸ÀÇ ±Þ¼ÓÇÑ º¸±ÞÀ¸·Î ÀÎÇØ ½Å¼ÓÇÑ Á¤·®, ¼öÁ¤ ¹× °üÂû¿¡ µµ¿òÀÌ µÇ´Â ºÐ¼®ÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. °ø°ø ±â°ü°ú ¹Î°£ ´Üü·ÎºÎÅÍ ¸¹Àº ÀÚ±ÝÀ» Áö¿ø¹Þ°í ÀÖ´Â ¹Ì±¹Àº ÷´Ü ¿¬±¸ ±â¹ý¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå¿¡¼­ ¼±µµÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. CDC¿¡ µû¸£¸é, 2023³â 4¿ù ¹Ì±¹ Àü¿ª¿¡ 7,000¸¸ °³ ÀÌ»óÀÇ Å×½ºÆ® ŰƮ°¡ ¹è¼ÛµÇ¾úÀ¸¸ç, SARS-CoV-2 µ¨Å¸ ¿ì¼¼ ±â°£°ú ¿À¹ÌÅ©·Ð ¿ì¼¼ ±â°£ µ¿¾È °¡Á¤ ³» Å×½ºÆ® »ç¿ëÀÌ ±ÞÁõÇß½À´Ï´Ù.

ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå ¼¼ºÐÈ­

ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀº À¯Çü, Á¦Ç°, ±â¼ú, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù. À¯Çüº°·Î ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀº ½Å¼Ó Ç׿ø °Ë»ç, ½Å¼Ó Ç×ü °Ë»ç, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ½Å¼Ó Ç׿ø °Ë»ç ºÎ¹®Àº 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Á¦Ç°º°·Î ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀº »ó¾÷¿ë ½Å¼Ó °Ë»ç ŰƮ¿Í »ó¾÷¿ë ½Å¼Ó °Ë»ç ŰƮ·Î ³ª´¹´Ï´Ù. »ó¾÷¿ë ½Å¼Ó °Ë»ç ŰƮ ºÐ¾ß´Â 2022³â Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±â¼úº°·Î ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀº Ãø¸é È帧 ºÐ¼®, °íü»ó, ÀÀÁý, ÀÀÁý, ¸é¿ª ½ºÆÌ ºÐ¼®, ¼¼Æ÷ ¼ººÐ ±â¹Ý µîÀ¸·Î ºÐ·ùµÇ¸ç, 2022³â¿¡´Â Ãø¸é È帧 ºÐ¼® ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀº Ç÷´ç °Ë»ç, °¨¿° °Ë»ç, ÀӽŠ¹× ºÒÀÓ °Ë»ç, ½ÉÀå ´ë»ç °Ë»ç, ±âŸ·Î ºÐ·ùµË´Ï´Ù. Ç÷´ç °Ë»ç ºÎ¹®ÀÌ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, ÀçÅà ÀÇ·á, Áø´Ü ¼¾ÅÍ, ±âŸ·Î ºÐ·ùµË´Ï´Ù. º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®ÀÌ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹ÀÌ 2022³â ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå Á¡À¯À²À» µ¶Â÷ÁöÇß½À´Ï´Ù.

F.Hoffmann-La Roche Ltd, Becton Dickinson and Co, ARKRAY Inc, Fujirebio Europe NV, bioMerieux SA, Cepheid, Meril Life Sciences Pvt Ltd, QIAGEN NV, OraSure Technologies Inc, Guangzhou Wondfo Biotech Co Ltd, Denka Co Ltd, Abbott Laboratories, Trinity Co, Abbott Laboratories, Trinity Biotech Plc, SD Biosensor Inc, Bio-Rad Laboratories Inc, Hologic Inc, DiaSorin SpA, Beckman Coulter Inc´Â ºÏ¹Ì ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷ Áß ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ºÏ¹ÌÀÇ ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå : ÁÖ¿ä »ê¾÷ ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • À¯Àü¼º Áúȯ ¹× °¨¿°¼º Áúȯ À¯º´·ü »ó½Â
    • Á¦Á¶¾÷ü¿¡ ÀÇÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °á°ú Á¤È®¼º¿¡ °üÇÑ ºÒÈ®½Ç¼º
  • ½ÃÀå ±âȸ
    • PCR ±â¼ú¿¡ ´ëÇÑ ±âÈ£ »ó½Â
  • ÇâÈÄ µ¿Çâ
    • ½Å¼Ó Ç׿ø °Ë»çÀÇ ±â¼ú Çõ½Å
  • ¿µÇ⠺м®

Á¦5Àå ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå : ºÏ¹Ì ½ÃÀå ºÐ¼®

  • ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå ¸ÅÃâ, 2020-2030³â

Á¦6Àå ºÏ¹ÌÀÇ ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå ºÐ¼® : À¯Çüº°

  • ½Å¼Ó Ç׿ø °Ë»ç
  • ½Å¼Ó Ç×ü °Ë»ç
  • ±âŸ

Á¦7Àå ºÏ¹ÌÀÇ ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • ½ÃÆÇ¿ë ½Å¼Ó °Ë»ç ŰƮ
  • ¾÷¹«¿ë ½Å¼Ó °Ë»ç ŰƮ

Á¦8Àå ºÏ¹ÌÀÇ ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå ºÐ¼® : ±â¼úº°

  • Ãø¹æÀ¯µ¿¾î¼¼ÀÌ
  • °í»ó
  • ÀÀÁý
  • ¸é¿ª½ºÆÌ ¾î¼¼ÀÌ
  • ¼¼Æ÷ ¼ººÐ ±â¹Ý

Á¦9Àå ºÏ¹ÌÀÇ ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå ºÐ¼® : ¿ëµµº°

  • Ç÷´çÄ¡ °Ë»ç
  • °¨¿°Áõ °Ë»ç
  • ¼øÈ¯ ´ë»ç °Ë»ç
  • ÀӽŠ¹× ºÒÀÓ °Ë»ç
  • ±âŸ

Á¦10Àå ºÏ¹ÌÀÇ ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø ¹× Áø·á¼Ò
  • Áø´Ü ¼¾ÅÍ
  • ÀçÅÃÀÇ·á
  • ±âŸ

Á¦11Àå ºÏ¹ÌÀÇ ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå : ±¹°¡º° ºÐ¼®

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ

Á¦12Àå ¾÷°è »óȲ

  • ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀÇ ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«

Á¦13Àå ±â¾÷ °³¿ä

  • F. Hoffmann-La Roche Ltd
  • Becton Dickinson and Co
  • ARKRAY Inc
  • Fujirebio Europe NV
  • bioMerieux SA
  • Cepheid
  • Meril Life Sciences Pvt Ltd
  • QIAGEN NV
  • OraSure Technologies Inc
  • Guangzhou Wondfo Biotech Co Ltd
  • Denka Co Ltd
  • Abbott Laboratories
  • Trinity Biotech Plc
  • SD Biosensor Inc
  • Bio-Rad Laboratories Inc
  • Hologic Inc
  • DiaSorin SpA
  • Beckman Coulter Inc

Á¦14Àå ºÎ·Ï

ksm 24.10.10

The North America rapid test kit market was valued at US$ 6,869.40 million in 2022 and is expected to reach US$ 10,462.82 million by 2030; it is estimated to record a CAGR of 5.4% from 2022 to 2030.

Rising Prevalence of Genetic and Infectious Diseases Fuels North America Rapid Test Kit Market

A 2022 report by MJH Life Sciences (US) estimates that 300,000 newborns worldwide are born with sickle cell disease every year. According to the CDC, 1 in 500 African Americans is affected by sickle cell disease. The latest World Malaria Report (WMR) 2022 from the World Health Organization (WHO) states that nearly 247 million new malaria cases were reported in the world in 2021, in comparison to 245 million cases that were logged in 2020. According to the same source, the number of deaths caused due to malaria was 619,000 in 2021.

Sickle SCAN is a rapid test for the identification of sickle cell anemia with high sensitivity and specificity. Rapid diagnostic tests (RDTs) help diagnose malaria by detecting the presence of malarial parasites in human blood. Where access to high-quality microscopy services is limited, radiological diagnosis techniques are used as an alternative for clinical or microscope-based diagnosis. The COVID-19 pandemic had a significant impact on the rapid test kits market. Nearly all diagnostic tests used real-time PCR for testing people who showed symptoms of SARS-CoV-2 infection. Rapid test kits are nearly ubiquitous, robust, and reliable. Rapid testing techniques that involve the amplification of specific stretches of DNA for genotyping, cloning, and single nucleotide variation analysis are used in most molecular biology labs. Thus, the increasing incidence of genetic and infectious diseases propels the growth of the rapid test kits market.

North America Rapid Test Kit Market Overview

The rapid adoption of gene synthesis and editing tools such as CRISPR and PCR in research and therapeutics necessitates assays that are helpful in terms of rapid quantification, alterations, and observation. The US, seeking significant funding from public and private organizations, is expected to invest significantly in advanced research methodologies and is expected to be in the leading position in the rapid test kits market. There was a rapid increase in at-home test use occurred between the SARS-CoV-2 Delta- and Omicron-predominant periods of the pandemic. According to the CDC, in April 2023, more than 70 million test kits were shipped across the US.

North America Rapid Test Kit Market Revenue and Forecast to 2030 (US$ Million)

North America Rapid Test Kit Market Segmentation

The North America rapid test kit market is segmented based on type, product, technology, application, end user, and country. Based on type, the North America rapid test kit market is segmented into rapid antigen testing, rapid antibody testing, and others. The rapid antigen testing segment held the largest market share in 2022.

In terms of product, the North America rapid test kit market is bifurcated into over-the-counter rapid testing kit and professional rapid testing kit. The over-the-counter rapid testing kit segment held a larger market share in 2022.

By technology, the North America rapid test kit market is segmented into lateral flow assay, solid phase, agglutination, immunospot assay, and cellular component-based. The lateral flow assay segment held the largest market share in 2022.

Based on application, the North America rapid test kit market is categorized into blood glucose testing, infectious disease testing, pregnancy and fertility, cardiometabolic testing, and others. The blood glucose testing segment held the largest market share in 2022.

In terms of end user, the North America rapid test kit market is segmented into hospital and clinics, home care, diagnostics centers, and others. The hospital and clinics segment held the largest market share in 2022.

Based on country, the North America rapid test kit market is segmented into the US, Canada, and Mexico. The US dominated the North America rapid test kit market share in 2022.

F. Hoffmann-La Roche Ltd, Becton Dickinson and Co, ARKRAY Inc, Fujirebio Europe NV, bioMerieux SA, Cepheid, Meril Life Sciences Pvt Ltd, QIAGEN NV, OraSure Technologies Inc, Guangzhou Wondfo Biotech Co Ltd, Denka Co Ltd, Abbott Laboratories, Trinity Biotech Plc, SD Biosensor Inc, Bio-Rad Laboratories Inc, Hologic Inc, DiaSorin SpA, and Beckman Coulter Inc are some of the leading players operating in the North America rapid test kit market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Rapid Test Kits Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Genetic and Infectious Diseases
    • 4.1.2 Strategic Initiatives by Manufacturers
  • 4.2 Market Restraints
    • 4.2.1 Uncertainties Related to Accuracy of Results
  • 4.3 Market Opportunities
    • 4.3.1 Increasing Preference for PCR Techniques
  • 4.4 Future Trends
    • 4.4.1 Innovations in Rapid Antigen Tests
  • 4.5 Impact Analysis

5. Rapid Test Kits Market - North America Market Analysis

  • 5.1 Overview
  • 5.2 Rapid Test Kits Market Revenue (US$ Mn), 2020 - 2030

6. North America Rapid Test Kits Market Analysis - by Type

  • 6.1 Overview
  • 6.2 Rapid Antigen Testing
    • 6.2.1 Overview
    • 6.2.2 Rapid Antigen Testing: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Rapid Antibody Testing
    • 6.3.1 Overview
    • 6.3.2 Rapid Antibody Testing: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Others
    • 6.4.1 Overview
    • 6.4.2 Others: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Rapid Test Kits Market Analysis - by Product

  • 7.1 Overview
  • 7.2 Over-the-Counter Rapid Testing Kit
    • 7.2.1 Overview
    • 7.2.2 Over-the-Counter Rapid Testing Kit: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Professional Rapid Testing Kit
    • 7.3.1 Overview
    • 7.3.2 Professional Rapid Testing Kit: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Rapid Test Kits Market Analysis - by Technology

  • 8.1 Overview
  • 8.2 Lateral Flow Assay
    • 8.2.1 Overview
    • 8.2.2 Lateral Flow Assay: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Solid Phase
    • 8.3.1 Overview
    • 8.3.2 Solid Phase: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Agglutination
    • 8.4.1 Overview
    • 8.4.2 Agglutination: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Immunospot Assay
    • 8.5.1 Overview
    • 8.5.2 Immunospot Assay: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Cellular-Component Based
    • 8.6.1 Overview
    • 8.6.2 Cellular-Component Based: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Rapid Test Kits Market Analysis - by Application

  • 9.1 Overview
  • 9.2 Blood Glucose Testing
    • 9.2.1 Overview
    • 9.2.2 Blood Glucose Testing: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Infectious Disease Testing
    • 9.3.1 Overview
    • 9.3.2 Infectious Disease Testing: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
    • 9.3.3 Infectious Disease Testing: Rapid Test Kits Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Cardiometabolic Testing
    • 9.4.1 Overview
    • 9.4.2 Cardiometabolic Testing: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Pregnancy and Fertility
    • 9.5.1 Overview
    • 9.5.2 Pregnancy and Fertility: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Rapid Test Kits Market Analysis - by End User

  • 10.1 Overview
  • 10.2 Hospital and Clinics
    • 10.2.1 Overview
    • 10.2.2 Hospital and Clinics: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Diagnostic Centers
    • 10.3.1 Overview
    • 10.3.2 Diagnostic Centers: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.4 Home-Care
    • 10.4.1 Overview
    • 10.4.2 Home-Care: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.5 Others
    • 10.5.1 Overview
    • 10.5.2 Others: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Rapid Test Kits Market - Country Analysis

  • 11.1 North America: Rapid Test Kits Market
    • 11.1.1 North America: Rapid Test Kits Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.1 United States
        • 11.1.1.1.1 Overview
      • 11.1.1.2 United States: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.2.1 United States: Rapid Test Kits Market Breakdown, by Type
        • 11.1.1.2.2 United States: Rapid Test Kits Market Breakdown, by Product
        • 11.1.1.2.3 United States: Rapid Test Kits Market Breakdown, by Technology
        • 11.1.1.2.4 United States: Rapid Test Kits Market Breakdown, by Application
        • 11.1.1.2.4.1 United States: Rapid Test Kits Market Breakdown, by Infectious Disease Testing
        • 11.1.1.2.5 United States: Rapid Test Kits Market Breakdown, by End User
      • 11.1.1.3 Canada
        • 11.1.1.3.1 Overview
      • 11.1.1.4 Canada: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.4.1 Canada: Rapid Test Kits Market Breakdown, by Type
        • 11.1.1.4.2 Canada: Rapid Test Kits Market Breakdown, by Product
        • 11.1.1.4.3 Canada: Rapid Test Kits Market Breakdown, by Technology
        • 11.1.1.4.4 Canada: Rapid Test Kits Market Breakdown, by Application
        • 11.1.1.4.4.1 Canada: Rapid Test Kits Market Breakdown, by Infectious Disease Testing
        • 11.1.1.4.5 Canada: Rapid Test Kits Market Breakdown, by End User
      • 11.1.1.5 Mexico: Rapid Test Kits Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.5.1 Overview
      • 11.1.1.6 Mexico
        • 11.1.1.6.1 Mexico: Rapid Test Kits Market Breakdown, by Type
        • 11.1.1.6.2 Mexico: Rapid Test Kits Market Breakdown, by Product
        • 11.1.1.6.3 Mexico: Rapid Test Kits Market Breakdown, by Technology
        • 11.1.1.6.4 Mexico: Rapid Test Kits Market Breakdown, by Application
        • 11.1.1.6.4.1 Mexico: Rapid Test Kits Market Breakdown, by Infectious Disease Testing
        • 11.1.1.6.5 Mexico: Rapid Test Kits Market Breakdown, by End User

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in the Rapid Test Kit Market
  • 12.3 Inorganic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Organic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Becton Dickinson and Co
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 ARKRAY Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Fujirebio Europe NV
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 bioMerieux SA
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Cepheid
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Meril Life Sciences Pvt Ltd
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 QIAGEN NV
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 OraSure Technologies Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Guangzhou Wondfo Biotech Co Ltd
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Denka Co Ltd
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments
  • 13.12 Abbott Laboratories
    • 13.12.1 Key Facts
    • 13.12.2 Business Description
    • 13.12.3 Products and Services
    • 13.12.4 Financial Overview
    • 13.12.5 SWOT Analysis
    • 13.12.6 Key Developments
  • 13.13 Trinity Biotech Plc
    • 13.13.1 Key Facts
    • 13.13.2 Business Description
    • 13.13.3 Products and Services
    • 13.13.4 Financial Overview
    • 13.13.5 SWOT Analysis
    • 13.13.6 Key Developments
  • 13.14 SD Biosensor Inc
    • 13.14.1 Key Facts
    • 13.14.2 Business Description
    • 13.14.3 Products and Services
    • 13.14.4 Financial Overview
    • 13.14.5 SWOT Analysis
    • 13.14.6 Key Developments
  • 13.15 Bio-Rad Laboratories Inc
    • 13.15.1 Key Facts
    • 13.15.2 Business Description
    • 13.15.3 Products and Services
    • 13.15.4 Financial Overview
    • 13.15.5 SWOT Analysis
    • 13.15.6 Key Developments
  • 13.16 Hologic Inc
    • 13.16.1 Key Facts
    • 13.16.2 Business Description
    • 13.16.3 Products and Services
    • 13.16.4 Financial Overview
    • 13.16.5 SWOT Analysis
    • 13.16.6 Key Developments
  • 13.17 DiaSorin SpA
    • 13.17.1 Key Facts
    • 13.17.2 Business Description
    • 13.17.3 Products and Services
    • 13.17.4 Financial Overview
    • 13.17.5 SWOT Analysis
    • 13.17.6 Key Developments
  • 13.18 Beckman Coulter Inc
    • 13.18.1 Key Facts
    • 13.18.2 Business Description
    • 13.18.3 Products and Services
    • 13.18.4 Financial Overview
    • 13.18.5 SWOT Analysis
    • 13.18.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦